Anti-leukotrienes versus long-acting beta2-agonists as add-on therapy to inhaled corticosteroids for chronic asthma

Long-acting β2-agonists in asthma: an overview of Cochrane systematic reviews

“…Three Cochrane systematic reviews directly relevant to the use of LABA in asthma have been published: (1) inhaled LABA for stable chronic asthma, first published in March 2003; 25 (2) regular treatment with LABA versus daily regular treatment with SABA in adults and children with stable asthma, first published in January 2003; 26 (3) LABA versus theophylline for maintenance treatment of asthma, first published in August 1999. 27 Three relevant protocols [28][29][30] have also been registered on the Cochrane Library at the time of writing in late 2004. These are related to the combined use of LABA and ICS in asthma, the potential superiority of the combination against ICS alone, and the potential superiority of the combination, if used together, in a single inhaler rather than in separate inhalers.…”

Long-acting β2-agonists in asthma: an overview of Cochrane systematic reviews

“…Three Cochrane systematic reviews directly relevant to the use of LABA in asthma have been published: (1) inhaled LABA for stable chronic asthma, first published in March 2003; 25 (2) regular treatment with LABA versus daily regular treatment with SABA in adults and children with stable asthma, first published in January 2003; 26 (3) LABA versus theophylline for maintenance treatment of asthma, first published in August 1999. 27 Three relevant protocols [28][29][30] have also been registered on the Cochrane Library at the time of writing in late 2004. These are related to the combined use of LABA and ICS in asthma, the potential superiority of the combination against ICS alone, and the potential superiority of the combination, if used together, in a single inhaler rather than in separate inhalers.…”

Long-acting β2-agonists in asthma: an overview of Cochrane systematic reviews

“…Three Cochrane systematic reviews directly relevant to the use of LABA in asthma have been published: (1) inhaled LABA for stable chronic asthma, first published in March 2003; 25 (2) regular treatment with LABA versus daily regular treatment with SABA in adults and children with stable asthma, first published in January 2003; 26 (3) LABA versus theophylline for maintenance treatment of asthma, first published in August 1999. 27 Three relevant protocols [28][29][30] have also been registered on the Cochrane Library at the time of writing in late 2004. These are related to the combined use of LABA and ICS in asthma, the potential superiority of the combination against ICS alone, and the potential superiority of the combination, if used together, in a single inhaler rather than in separate inhalers.…”

Long-acting β2-agonists in asthma: an overview of Cochrane systematic reviews

“…Three Cochrane systematic reviews directly relevant to the use of LABA in asthma have been published: (1) inhaled LABA for stable chronic asthma, first published in March 2003; 25 (2) regular treatment with LABA versus daily regular treatment with SABA in adults and children with stable asthma, first published in January 2003; 26 (3) LABA versus theophylline for maintenance treatment of asthma, first published in August 1999. 27 Three relevant protocols [28][29][30] have also been registered on the Cochrane Library at the time of writing in late 2004. These are related to the combined use of LABA and ICS in asthma, the potential superiority of the combination against ICS alone, and the potential superiority of the combination, if used together, in a single inhaler rather than in separate inhalers.…”